Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in J Clin Invest

Retrieve available abstracts of 43 articles:
HTML format



Single Articles


    March 2024
  1. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    PubMed     Abstract available


    January 2024
  2. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available


  3. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    PubMed     Abstract available


    December 2023
  4. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    PubMed     Abstract available


  5. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    PubMed     Abstract available


    November 2023
  6. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed     Abstract available


    October 2023
  7. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    PubMed     Abstract available


  8. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    PubMed     Abstract available


  9. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    PubMed     Abstract available


    September 2023
  10. KONEN JM, Rodriguez BL, Wu H, Fradette JJ, et al
    Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.
    J Clin Invest. 2023;133:e163128.
    PubMed     Abstract available


    August 2023
  11. MALCHERS F, Nogova L, van Attekum MH, Maas L, et al
    Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
    J Clin Invest. 2023 Aug 22:e170217. doi: 10.1172/JCI170217.
    PubMed     Abstract available


    July 2023
  12. ATTIG J, Pape J, Doglio L, Kazachenka A, et al
    Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin.
    J Clin Invest. 2023;133:e164397.
    PubMed     Abstract available


    June 2023
  13. NARDI F, Perurena N, Schade AE, Li ZH, et al
    Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer.
    J Clin Invest. 2023 Jun 29:e167651. doi: 10.1172/JCI167651.
    PubMed     Abstract available


    April 2023
  14. SALMON M, Alvarez-Diaz R, Fustero-Torre C, Brehey O, et al
    Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    J Clin Invest. 2023;133:e164413.
    PubMed     Abstract available


  15. HU Z, Yu X, Ding R, Liu B, et al
    Glycolysis drives STING signaling to facilitate dendritic cell antitumor function.
    J Clin Invest. 2023;133:e166031.
    PubMed     Abstract available


    March 2023
  16. JASPERS JE, Khan JF, Godfrey WD, Lopez AV, et al
    IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
    J Clin Invest. 2023 Mar 23:e166028. doi: 10.1172/JCI166028.
    PubMed     Abstract available


    February 2023
  17. TAN X, Xiao GY, Wang S, Shi L, et al
    EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer.
    J Clin Invest. 2023 Feb 9:e165863. doi: 10.1172/JCI165863.
    PubMed     Abstract available


    January 2023
  18. WANG S, Rong R, Yang DM, Fujimoto J, et al
    Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
    J Clin Invest. 2023;133:e160330.
    PubMed     Abstract available


  19. HU H, Cheng R, Wang Y, Wang X, et al
    Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
    J Clin Invest. 2023;133:e153470.
    PubMed     Abstract available


  20. DING L, Chen X, Zhang W, Dai X, et al
    Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.
    J Clin Invest. 2023;133:e154754.
    PubMed     Abstract available


    December 2022
  21. ZHANG S, You X, Zheng Y, Shen Y, et al
    The UBE2C/CDH1/DEPTOR axis is an oncogene-tumor suppressor cascade in lung cancer cells.
    J Clin Invest. 2022 Dec 22:e162434. doi: 10.1172/JCI162434.
    PubMed     Abstract available


    November 2022
  22. LI K, Liu Y, Ding Y, Zhang Z, et al
    BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


  23. ZHANG H, Zhu X, Friesen TJ, Kwak JW, et al
    Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    September 2022
  24. NIE M, Chen N, Pang H, Jiang T, et al
    Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
    J Clin Invest. 2022 Sep 1. pii: 160152. doi: 10.1172/JCI160152.
    PubMed     Abstract available


  25. WANG H, Lin Z, Nian Z, Zhang W, et al
    Hematopoietic transcription factor GFI1 promotes anchorage independence by sustaining ERK activity in cancer cells.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    August 2022
  26. HE Y, Luo W, Liu Y, Wang Y, et al
    IL20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer.
    J Clin Invest. 2022 Aug 25. pii: 157917. doi: 10.1172/JCI157917.
    PubMed     Abstract available


    June 2022
  27. YAN D, Huelse JM, Kireev D, Tan Z, et al
    MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
    J Clin Invest. 2022 Jun 16. pii: 150517. doi: 10.1172/JCI150517.
    PubMed     Abstract available


  28. DEFAYE M, Iftinca MC, Gadotti VM, Basso L, et al
    The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    May 2022
  29. NANJO S, Wu W, Karachaliou N, Blakely CM, et al
    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.
    J Clin Invest. 2022 May 17. pii: 145099. doi: 10.1172/JCI145099.
    PubMed     Abstract available


    April 2022
  30. WAARTS MR, Stonestrom AJ, Park YC, Levine RL, et al
    Targeting mutations in cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    March 2022
  31. XU C, Jin G, Wu H, Cui W, et al
    SIRPgamma-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    February 2022
  32. MANABE T, Bivona TG
    Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


  33. TSAI YS, Woodcock MG, Azam SH, Thorne LB, et al
    Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    November 2021
  34. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    October 2021
  35. ZHANG W, Sun Y, Bai L, Zhi L, et al
    RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11.
    J Clin Invest. 2021 Oct 5. pii: 152067. doi: 10.1172/JCI152067.
    PubMed     Abstract available


    September 2021
  36. HEISHIMA K, Sugito N, Soga T, Nishikawa M, et al
    Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    August 2021
  37. SU SF, Ho H, Li JH, Wu MF, et al
    DNA methylome and transcriptome landscapes of cancer-associated fibroblasts reveal a smoking-associated malignancy index.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    May 2021
  38. MAIMON A, Levi-Yahid V, Ben-Meir K, Halpern A, et al
    Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  39. LIANG W, Chen Z, Li C, Liu J, et al
    Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    January 2021
  40. SEHGAL K, Barbie DA
    Targeting the mutant p53 secretome.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  41. AMOEDO ND, Sarlak S, Obre E, Esteves P, et al
    Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  42. CHO J, Min HY, Lee HJ, Hyun SY, et al
    RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  43. TAN X, Shi L, Banerjee P, Liu X, et al
    A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.